
-
US fencer disqualified for not facing transgender rival
-
'Everyone worried' by Trump tariffs in France's champagne region
-
Italy's Brignone suffers broken leg with Winter Olympics looming
-
Iyer blitz powers Kolkata to big IPL win over Hyderabad
-
Russian soprano Netrebko to return to London's Royal Opera House
-
French creche worker gets 25 years for killing baby with drain cleaner
-
UK avoids worst US tariffs post-Brexit, but no celebrations
-
Canada imposing 25% tariff on some US auto imports
-
Ruud wants 'fair share' of Grand Slam revenue for players
-
Lesotho, Africa's 'kingdom in the sky' jolted by Trump
-
Trump's trade math baffles economists
-
Gaza heritage and destruction on display in Paris
-
'Unprecedented crisis' in Africa healthcare: report
-
Pogacar gunning for blood and thunder in Tour of Flanders
-
Macron calls for suspension of investment in US until tariffs clarified
-
Wall St leads rout as world reels from Trump tariffs
-
Mullins gets perfect National boost with remarkable four-timer
-
Trump tariffs hammer global stocks, dollar and oil
-
Authors hold London protest against Meta for 'stealing' work to train AI
-
Tate Modern gifted 'extraordinary' work by US artist Joan Mitchell
-
Mexico president welcomes being left off Trump's new tariffs list
-
Tonali eager to lead Newcastle back into Champions League
-
Lesotho hardest hit as new US tariffs rattle Africa
-
Stellantis pausing some Canada, Mexico production over Trump auto tariffs
-
Rising odds asteroid that briefly threatened Earth will hit Moon
-
Italy reels from Brignone broken leg with Winter Olympics looming
-
Is the Switch 2 worth the price? Reviews are mixed
-
Ancelotti’s tax trial wraps up in Spain with prosecutors seeking jail
-
Civilians act to bring aid to Myanmar earthquake victims
-
US trade gap narrows in February ahead of bulk of Trump tariffs
-
Stocks, dollar and oil sink as gold hits high on Trump tariffs
-
Countries eye trade talks as Trump tariff blitz roils markets
-
Arsenal defender Gabriel out for rest of the season
-
Trump says US to emerge 'stronger' as markets tumble over tariffs
-
Wiegman says Belgium games can aid England's women's Euros title defence
-
Prosecutors demand jail term for Ancelotti for tax fraud
-
Syria accuses Israel of deadly destabilisation campaign
-
Skiing World Cup champion Brignone suffers broken leg
-
Iconic Paris hotel Lutetia taken over by Mandarin Oriental
-
Nepal capital chokes as wildfires rage
-
AI could impact 40 percent of jobs worldwide: UN
-
'Shocking': US tariffs worse than feared for Vietnamese exporters
-
Liverpool's Slot happy to let Premier League title bid take its course
-
USA sole bidder for 2031 Women's World Cup, UK set to host in 2035
-
Tesla sales fall again in Germany amid Musk backlash
-
Italy's skiing champion Brignone air-lifted to hospital after crash
-
US trade partners eye talks after Trump tariff blitz
-
Evenepoel adds Tour de Romandie to comeback programme
-
Defending champion I Am Maximus heads final field for Grand National
-
Rubio says US committed to NATO - but tells allies to spend more
RYCEF | 0.2% | 9.8 | $ | |
RBGPF | -0.41% | 67.72 | $ | |
SCS | -5.62% | 10.85 | $ | |
RIO | -1.93% | 58.765 | $ | |
CMSC | -0.94% | 22.29 | $ | |
GSK | 3.62% | 39.055 | $ | |
BTI | 4.27% | 42.045 | $ | |
AZN | 2.74% | 74.255 | $ | |
RELX | 1.23% | 51.615 | $ | |
NGG | 5.26% | 69.43 | $ | |
VOD | 2.67% | 9.37 | $ | |
BCE | 2.63% | 22.41 | $ | |
JRI | -1.56% | 12.84 | $ | |
BP | -7.28% | 31.515 | $ | |
BCC | -7.62% | 94.84 | $ | |
CMSD | -0.73% | 22.665 | $ |

Join Enlivex Therapeutics' Exclusive Live Investor Webinar and Q&A Session on December 3
Enlivex Therapeutics Ltd. (Nasdaq:ENLV)(the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, is pleased to invite investors to a webinar on December 3, 2024, at 11:00 a.m. ET.
The exclusive event, hosted by RedChip Companies, will feature Enlivex Therapeutics Chief Executive Officer Oren Hershkovitz who will share insight into the Company's lead product, Allocetra™, insight into the clinical status, and 2025 planned catalysts.
Allocetra™ is an off-the-shelf, cell therapy technology that reprograms non-homeostatic macrophages to their optimal functioning state, addressing critical unmet needs in conditions like osteoarthritis, sepsis, and psoriatic arthritis. With Phase I/II clinical trials showing promising results and targeting multi-billion-dollar markets, Allocetra™ has the potential to redefine treatment paradigms for inflammatory and autoimmune diseases.
To register for the free webinar, please visit:
https://redchip.zoom.us/webinar/register/WN_jJyhETX6SQOSD6k3JhkfuA#/registration
A live Q&A session will follow the presentation. Questions can be pre-submitted to [email protected] or online during the live event.
ABOUT ENLIVEX
Enlivex is a clinical stage macrophage reprogramming immunotherapy company developing Allocetra™, a universal, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. Resetting non-homeostatic macrophages into their homeostatic state is critical for immune system rebalancing and resolution of life-threatening and life debilitating conditions. For more information, visit http://www.enlivex.com.
Safe Harbor Statement: This press release contains forward-looking statements, which may be identified by words such as "expects," "plans," "projects," "will," "may," "anticipates," "believes," "should," "would", "could," "intends," "estimates," "suggests," "has the potential to" and other words of similar meaning, including statements regarding expected cash balances, market opportunities for the results of current clinical studies and preclinical experiments, the effectiveness of, and market opportunities for, ALLOCETRA TM programs. All such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that forward-looking statements involve risks and uncertainties that may affect Enlivex's business and prospects, including the risks that Enlivex may not succeed in generating any revenues or developing any commercial products; that the products in development may fail, may not achieve the expected results or effectiveness and/or may not generate data that would support the approval or marketing of these products for the indications being studied or for other indications; that ongoing studies may not continue to show substantial or any activity; and other risks and uncertainties that may cause results to differ materially from those set forth in the forward-looking statements. The results of clinical trials in humans may produce results that differ significantly from the results of clinical and other trials in animals. The results of early-stage trials may differ significantly from the results of more developed, later-stage trials. The development of any products using the ALLOCETRA TM product line could also be affected by a number of other factors, including unexpected safety, efficacy or manufacturing issues, additional time requirements for data analyses and decision making, the impact of pharmaceutical industry regulation, the impact of competitive products and pricing and the impact of patents and other proprietary rights held by competitors and other third parties. In addition to the risk factors described above, investors should consider the economic, competitive, governmental, technological and other factors discussed in Enlivex's filings with the Securities and Exchange Commission, including in the Company's most recent Annual Report on Form 20-F filed with the Securities and Exchange Commission. The forward-looking statements contained in this press release speak only as of the date the statements were made, and we do not undertake any obligation to update forward-looking statements, except as required under applicable law.
Contact:
Dave Gentry, CEO
RedChip Companies, Inc.
1-407-644-4256
[email protected]
SOURCE: Enlivex Therapeutics Ltd.
G.Stevens--AMWN